木瓜直播

Meeting Coverage >

ASH: Hematology

Sickle Cell Disease Tied to Worse COVID-19 Outcomes

Black patients seem to be at higher risk for certain COVID-19 complications, death

Three-Drug Regimen Reduces Myeloma Treatment Burden

Efficacy maintained with addition of SQ daratumumab to pomalidomide, dexamethasone

Survival Bump With Oral AML Maintenance

Ten-month OS gain, doubling of RFS with oral azacitidine in transplant-ineligible patients

Study: Adding Aspirin to DOAC? Better Have a Good Reason

Combination tied to marked increase in bleeding risk

'Off-the-Shelf' Therapy Active After CAR T-Cell Failure

Bispecific antibody mosunetuzumab targets CD3, CD20; needs no ex vivo T-cell processing

Study Bolsters Case for Novel Xarelto Formulation for Kids

Pharmacokinetic data indicate appropriate dosing schemes across wide range of weight categories

Cancer-VTE Trial Falls Short

High dropout rate undermines rivaroxaban prophylaxis trial

Chemo-Free Tx Tops Best Option in Younger CLL Patients

Improved overall survival and safety with ibrutinib-based therapy

Combination Regimen Extends PFS in Myeloma

Large benefit but relevance of comparator questioned

$2 Test Could Transform Sickle Cell Dx in Africa

May have applications in high-income countries as well

ASH Offers Early Look at Updated SCD Guidelines

Experts formulated >50 recommendations on sickle cell disease

Add-On Drugs Could Boost Efficacy, Tolerability of CAR T-Cell Therapies

Studies test addition of targeted agents, immunotherapy

Novel Therapies Offer Hope in Sickle Cell Disease

Studies explore possibility of parental donor; boosting fetal hemoglobin production

CAR T-Cell Responses Prove Durable in ALL, DLBCL

Two studies demonstrate long-term control in relapsed/refractory disease

Cutting Chemo Cycles Feasible in Younger DLBCL Patients

Patients, ages 18-60, fare well with four cycles of CHOP instead of six

Ibrutinib Alone Wins in Older CLL Patients

Adding rituximab offered no added benefit

Sneak Peek at Practice-Changing Research From ASH 2018

"Big trials, big results," plus sickle cell disease and CAR T-cell therapies

Mixed Results with Regimens for Older AML Patients

Positive data with venetoclax, liposomal cytarabine-daunorubicin

Amyloidosis Treatments Miss the Heart of the Problem

Only modest improvement in end organ function

Bangladesh-Boston Collaborate on ASCT Center

Two dozen patients undergo successful stem cell transplant in Dhaka

Can Patients With Stable CML Stop Drug Therapy?

Studies examine TKI cessation and dose reduction

Survival Boost With Liposomal Tx in Older AML Patients

Agent may also provide a bridge to successful transplant

Novel Sickle Cell Tx Shows Promise for Pain Crises

Monoclonal antibody tied to lower incidence of adverse events

OncoBlog: Driving the CAR to a Cancer Cure?

Is immunotherapy with chimeric antigen receptor (CAR)-directed T cells the "next big thing" in oncology? Presentations and discussion at a recent conference suggest the technology has considerable promise -- but will it qualify as a breakthrough? OncoBlog is a blog by the Medpage Today staff for readers with an interest in oncology. This post comes from Charles Bankhead.

Gene Therapy Works in SCID With No Risk of Leukemia

NEW ORLEANS -- Genetic therapy appeared to restore the immune system of patients with X-linked severe combined immunodeficiency (SCID), but without leading to leukemia as a side effect, researchers reported here.

Infection High in Myeloma, with High Mortality

ATLANTA -- More than a fifth of patients with multiple myeloma died of infection within a year of diagnosis, Swedish investigators reported here.

Oral Azacitidine Safe, Effective in Low-Risk MDS

ATLANTA -- Oral azacitidine (Vidaza) given for up to 21 days per 4-week cycle for myelodysplastic syndrome appeared safe and effective in patients with lower-risk disease, a researcher said here.

New Combo Replaces CHOP for Lymphoma

ATLANTA - The combination chemotherapy known as CHOP, used for nonHodgkin's lymphoma, is rapidly being replaced by bendamustine (Treanda), frequently combined with rituximab (Rituxan), researchers reported.

Children OK with Long-Term Exjade

ATLANTA -- Children with thalassemia and treated with the anti-iron overload drug deferasirox (Exjade) appear to tolerate the treatment for at least as long as 3 years while serum iron levels fell, researchers said here.

Extended Apixaban Stops VTE Recurrence

ATLANTA -- Apixaban taken for an additional year after standard venous thromboembolism (VTE) treatment reduced recurrent events in a placebo-controlled trial, researchers said.

Polycythemia Vera Better with Low Hematocrit

ATLANTA -- Maintaining patients with polycythemia vera at hematocrit levels below 45% reduced thrombotic complications without increasing rates of other serious adverse events.

ASH: Drugs Effective in Chronic ITP Not Appropriate as First-Line Treatment

SAN FRANCISCO -- Rituximab (Rituxan) and eltrombopag (Promacta) are "too aggressive and too expensive" for use as first-line therapies against chronic idiopathic thrombocytopenic purpura, agreed participants in an exclusive 木瓜直播 roundtable discussion.